Because the frequency of MYD88 L265P mutation is much lower in other related chronic B cell lymphoproliferative disorders such as splenic marginal zone B cell lymphoma, multiple myeloma, and chronic lymphocytic leukemia (<10%), the presence of this mutation could be a very useful diagnostic marker to distinguish WM from other B cell-related disorders and might represent a potential therapeutic target for WM [18, 19]. This evidence concerns the gene MYD88 and AL amyloidosis.